Key inclusion criteria:

   1. Documented diagnosis of EoE by endoscopy prior to or at screening

   2. History of on average at least 2 episodes of dysphagia (with intake of solids off
   anti-inflammatory therapy) per week in the 4 weeks prior to screening and on average
   at least 2 episodes of documented dysphagia per week in the weeks between screening
   and baseline; dysphagia is defined as trouble swallowing solid food, or having solid
   food stick, by participant report

   3. Must remain on a stabilized diet for at least 6 weeks prior to screening and during
   the course of the study; stable diet is defined as no initiation of single or multiple
   elimination diets or reintroduction of previously eliminated food groups

   4. Documented history of or presence of any of the following: allergic disease (e.g,
   allergic asthma, allergic rhinitis, atopic dermatitis (AD), or food allergies),
   peripheral eosinophil counts ≥0.25 GI/L, or serum total Immunoglobulin E (IgE) ≥100
   kU/L

Key Exclusion Criteria:

   1. Prior participation in a dupilumab (anti-IL-4R) clinical trial

   2. Other causes of esophageal eosinophilia or the following diseases: hypereosinophilic
   syndromes, Churg-Strauss vasculitis, and eosinophilic gastroenteritis

   3. History of achalasia, active Helicobacter pylori infection, Crohn's disease,
   ulcerative colitis, celiac disease, and prior esophageal surgery prior to screening

   4. Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9
   to10 mm) upper endoscope or any critical esophageal stricture that requires dilation
   at screening

   5. History of bleeding disorders or esophageal varices

   6. Use of chronic aspirin, nonsteroidal agents, or anti-coagulants within 2 weeks prior
   to screening. Participants should not stop these agents solely to become eligible for
   entry into this study

   7. Treatment with an investigational drug within 2 months or within 5 half-lives (if
   known), whichever is longer, prior to screening

   8. Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids
   within 3 months prior to screening

   9. Use of inhaled (pulmonary or nasal) topical corticosteroids within 3 months prior to
   screening and during the study, except stable dose for at least 3 months prior to
   screening biopsy, which cannot be changed during the study

10. Treatment with oral immunotherapy (OIT) within 6 months prior to screening

11. Allergen immunotherapy unless on stable dose for at least 1 year prior to screening

12. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
   during the study

Note: The list of inclusion/ exclusion criteria provided above is not intended to contain
all considerations relevant to a participant's potential participation in this clinical
trial.